Review: Typhonium flagelliforme as a source of functional ingredients and medicinal leads with evidence, safety, and research priorities
Asian Journal of Tropical Biotechnology · 30.06.2026 · 23 (1)
DOI: 10.13057/biotek/c230106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Tropical Biotechnology, online erschienen am 30.06.2026. Verfasst von RANI RACHMA ASTINING PUTRI und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Putri RRA, Manullang RH, Andrianto R, Salsabila S, Izdihar RS, Setyawan AD. 2026. Review: Typhonium flagelliforme as a source of functional ingredients and medicinal leads with evidence, safety, and research priorities. Asian J Trop Biotechnol 23 (1): c230106. https://doi.org/10.13057/biotek/c230106. Typhonium flagelliforme (Araceae), commonly known as rodent tuber or keladi tikus, is widely promoted in Southeast Asia as a medicinal plant and is increasingly discussed as a prospective food or functional ingredient. This critical narrative review draws on 151 sources, including 35 publications explicitly focused on T. flagelliforme or rodent tuber, and evaluates its identity, ecology, cultivation, traditional uses, proposed food applications, phytochemistry, pharmacology, safety, and translational readiness. The strongest evidence concerns anticancer-related activity: crude extracts and fractions have produced cytotoxic, antiproliferative, invasion-inhibitory, apoptosis-associated, or antitumor responses in cell and animal models. However, no defensible pooled anticancer IC₅₀ range could be calculated because plant organs, extracts, cell models, exposure periods, assays, and controls were heterogeneous. One ethanol-tuber antioxidant study reported a 2,2-diphenyl-1-picrylhydrazyl (DPPH) IC₅₀ of 74.359 µg/mL, but this chemical assay does not demonstrate therapeutic efficacy. Immunomodulatory, antimicrobial, and hepatic findings remain preliminary, and no controlled clinical evidence demonstrates efficacy for cancer or any other human disease. Evidence for routine food use is substantially weaker and lacks adequate data on nutrient composition, calcium oxalate, validated processing, palatability, and long-term intake. Significant priorities include voucher-based authentication, validated extract fingerprints, bioassay-guided fractionation, normal-cell selectivity, repeated-dose toxicology, pharmacokinetics, and product-specific regulatory evaluation. Without this foundation, the plant's established preclinical promise cannot translate responsibly to human applications.
Zitieren
APA
PUTRI, R. R. A., MANULLANG, R. H., ANDRIANTO, R., SALSABILA, S., IZDIHAR, R. S., SARI, S. L. A., & SETYAWAN, A. D. (2026). Review: Typhonium flagelliforme as a source of functional ingredients and medicinal leads with evidence, safety, and research priorities. Asian Journal of Tropical Biotechnology, 23(1). https://doi.org/10.13057/biotek/c230106
Vancouver
PUTRI RRA, MANULLANG RH, ANDRIANTO R, SALSABILA S, IZDIHAR RS, SARI SLA, et al. Review: Typhonium flagelliforme as a source of functional ingredients and medicinal leads with evidence, safety, and research priorities. Asian Journal of Tropical Biotechnology. 2026;23(1). doi:10.13057/biotek/c230106
BibTeX
@article{PUTRI2026,
author = {PUTRI, RANI RACHMA ASTINING and MANULLANG, RAYMOND HAMONANGAN and ANDRIANTO, ROI and SALSABILA, SIBRINA and IZDIHAR, RINOA SALSABILA and SARI, SITI LUSI ARUM and SETYAWAN, AHMAD DWI},
title = {Review: Typhonium flagelliforme as a source of functional ingredients and medicinal leads with evidence, safety, and research priorities},
journal = {Asian Journal of Tropical Biotechnology},
year = {2026},
volume = {23},
number = {1},
doi = {10.13057/biotek/c230106}
}
EUVIMED